Skip to content

ONCOVISTA INNOVATIVE THERAPIES, INC: 10-Q filed 2012-08-14

What ONCOVISTA INNOVATIVE THERAPIES, INC reported in its quarterly report filed 2012-08-14 (fiscal Q2 2012): 25 published measures, 70 facts as tagged in accession 0001144204-12-045889.

This filing

Form
10-Q (quarterly report)
Filed
2012-08-14
Fiscal period
fiscal Q2 2012
Accession
0001144204-12-045889 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ONCOVISTA INNOVATIVE THERAPIES, INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-06-301,306,821USD
At 2011-12-312,188,619USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-06-30-996,161USD
At 2011-12-31-124,028USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-06-301,165,612USD
At 2011-12-312,125,229USD
At 2011-06-302,748,515USD
At 2010-12-313,524,496USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-959,874USD182
2011-01-01 to 2011-06-30-773,122USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2012-04-01 to 2012-06-300USD91
2012-01-01 to 2012-06-300USD182
2011-04-01 to 2011-06-300USD91
2011-01-01 to 2011-06-300USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-06-30-21,189,724USD
At 2011-12-31-20,279,739USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-06-306,732USD
At 2011-12-3110,222USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-06-3037,595USD182
2011-01-01 to 2011-06-3071,373USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-04-01 to 2012-06-30-565,493USD91
2012-01-01 to 2012-06-30-1,053,094USD182
2011-04-01 to 2011-06-30-552,941USD91
2011-01-01 to 2011-06-30-1,011,335USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-06-301,300,089USD
At 2011-12-312,178,397USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2012-04-01 to 2012-06-303,476USD91
2012-01-01 to 2012-06-306,845USD182
2011-04-01 to 2011-06-3012,636USD91
2011-01-01 to 2011-06-3013,473USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-06-302,302,982USD
At 2011-12-312,312,647USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-06-30825,005USD
At 2011-12-31818,522USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2012-04-01 to 2012-06-30565,493USD91
2012-01-01 to 2012-06-301,053,094USD182
2011-04-01 to 2011-06-30552,941USD91
2011-01-01 to 2011-06-301,011,335USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-04-01 to 2012-06-30341,402USD91
2012-01-01 to 2012-06-30640,227USD182
2011-04-01 to 2011-06-30179,940USD91
2011-01-01 to 2011-06-30341,990USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-06-3021,627,868shares
At 2011-12-3121,370,725shares

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-06-3039,458USD
At 2011-12-3139,458USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-06-30-32,726USD
At 2011-12-31-29,236USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-06-301,127,331USD
At 2011-12-311,003,580USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2012-04-01 to 2012-06-30-250,557USD91
2012-01-01 to 2012-06-30-909,985USD182
2011-04-01 to 2011-06-30-577,932USD91
2011-01-01 to 2011-06-30-1,317,437USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-04-01 to 2012-06-30224,091USD91
2012-01-01 to 2012-06-30412,867USD182
2011-04-01 to 2011-06-30373,001USD91
2011-01-01 to 2011-06-30669,345USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-01-01 to 2012-06-303,490USD182
2011-01-01 to 2011-06-303,251USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2012-04-01 to 2012-06-30883USD91
2012-01-01 to 2012-06-30883USD182
2011-04-01 to 2011-06-307,049USD91
2011-01-01 to 2011-06-304,920USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2012-04-01 to 2012-06-30314,936USD91
2012-01-01 to 2012-06-30143,109USD182
2011-04-01 to 2011-06-30-24,991USD91
2011-01-01 to 2011-06-30-306,102USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-06-306,483USD182
2011-01-01 to 2011-06-3086,639USD181

Inspect the source

Entity
ONCOVISTA INNOVATIVE THERAPIES, INC / CIK 0001094847
Captured
SEC response SHA-256
034ecc655296ec55707e21b2011e7bc05aab2b1bd1d5e47c9d631e0e4310eac5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001094847.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))